BridgeBio Pharma Operating Expenses 2018-2025 | BBIO

BridgeBio Pharma operating expenses for the twelve months ending March 31, 2025 were $0.825B, a 17.96% increase year-over-year.

  • BridgeBio Pharma annual operating expenses for 2024 were $0.815B, a 32.14% increase from 2023.
  • BridgeBio Pharma annual operating expenses for 2023 were $0.617B, a 4.55% increase from 2022.
  • BridgeBio Pharma annual operating expenses for 2022 were $0.59B, a 8.74% decline from 2021.

BridgeBio Pharma Operating Expenses 2018-2025 | BBIO

  • BridgeBio Pharma annual operating expenses for 2024 were $0.815B, a 32.14% increase from 2023.
  • BridgeBio Pharma annual operating expenses for 2023 were $0.617B, a 4.55% increase from 2022.
  • BridgeBio Pharma annual operating expenses for 2022 were $0.59B, a 8.74% decline from 2021.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$15.5B
Dr Reddy's Laboratories (RDY)$11.4B
Bausch Health Cos (BHC)$1.9B
Supernus Pharmaceuticals (SUPN)$1.7B
Amphastar Pharmaceuticals (AMPH)$1.1B
Personalis (PSNL)$282M
Taysha Gene Therapies (TSHA)$254M
Assembly Biosciences (ASMB)$75M
Sol-Gel Technologies (SLGL)$15M
Evoke Pharma (EVOK)$3M
Teligent (TLGT)$0M